Praxis Precision Medicines Inc

NASDAQ:PRAX  
47.26
+0.94 (+2.03%)
4:20:00 PM EDT: $47.26 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)982.18M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.21 Million
Adjusted EPS-$3.20
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Praxis Precision Medicines Inc Stock, NASDAQ:PRAX

99 High Street, 30th floor, Boston, Massachusetts 02110
United States of America
Phone: +1.617.300.8460
Number of Employees: 116

Description

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.